Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Asahi Kaisei Corp. (OTC: AHKSY).

Full DD Report for AHKSY

You must become a subscriber to view this report.

Recent News from (OTC: AHKSY)

Asahi Kasei Corp. ADR 2017 Q4 - Results - Earnings Call Slides
The following slide deck was published by Asahi Kasei Corp. ADR in conjunction with their 2017 Q4 earnings Read more ...
Source: SeekingAlpha
Date: February, 07 2018 14:51
Asahi Kasei Corp. ADR 2017 Q2 - Results - Earnings Call Slides
The following slide deck was published by Asahi Kasei Corp. ADR in conjunction with their 2017 Q2 earnings Read more ...
Source: SeekingAlpha
Date: November, 07 2017 12:59
Evotec collaborates with Japan's Asahi Kasei Pharma on drug discovery
Evotec AG ( OTC:EVOTF ) announces  that it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation  ( OTCPK:AHKSY ). More news on: Evotec AG, Asahi Kasei Corp. ADR, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: January, 19 2017 06:52
GMO International Active EAFE Strategy Q3 2016 Commentary
By Umair Tariq GMO International Active EAFE Strategy commentary for the third quarter ended September 30, 2016. Q3 2016 hedge fund letters Q2 2016 hedge fund letters Performance The GMO International Active EAFE Strategy was 0.4 percentage points behind the MSCI EAFE ben...
Source: SeekingAlpha
Date: November, 12 2016 14:39
A Year Of Scandal: The Beginning Of The End Of Cronyism In Japan?
A Year of Scandal: The Beginning of the End of Cronyism in Japan? If you had to choose one word to encapsulate the theme of the past year in Japanese media, it would be simple: scandal . Between the public funds scandal that has seen Tokyo's governor Masuzoe forced to resign or the ong...
Source: SeekingAlpha
Date: July, 05 2016 16:38
Array Bio licenses TrkA inhibitors to Asahi Kasei Pharma in Asia for up to $76M
Array BioPharma ( ARRY +3.1% ) inks a strategic collaboration with Tokyo-based Asahi Kasei Pharma ( OTC:AHKSF )( OTCPK:AHKSY ) to develop and commercialize certain Tropomyosin receptor kinase A (TrkA) inhibitors, including ARRY-954, for pain, inflammation and other non-cancer indications...
Source: SeekingAlpha
Date: March, 31 2016 10:44


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AHKSY.

About Asahi Kaisei Corp. (OTC: AHKSY)

Logo for Asahi Kaisei Corp. (OTC: AHKSY)

Asahi Kasei Corporation, with consolidated sales of billion, provides innovative solutions based in chemistry and materials science to a diverse range of markets including fibers, chemicals, consumer products, housing, construction, electronics, and health care. On October , , all core operations were transferred to seven wholly owned constituent corporations as autonomous operating business units. Asahi Kasei Corporation, as the parent company, functions as a holding company for group operations.


Contact Information



Current Management

  • Toshio Asano / President
  • Taketsugu Fujiwara / Vice Chairman

Current Share Structure

  • Market Cap: $18,170,890,280 - 03/09/2018
  • Authorized: 4,000,000,000 - 03/31/2008
  • Issue and Outstanding: 1,402,616,000 - 02/28/2011


Recent Filings from (OTC: AHKSY)

Post-effective amendment to a previously filed F-6
Filing Type: F-6 POSFiling Source: edgar
Filing Date: September, 29 2017



Daily Technical Chart for (OTC: AHKSY)

Daily Technical Chart for (OTC: AHKSY)

Stay tuned for daily updates and more on (OTC: AHKSY)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: AHKSY)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

DD Report



Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AHKSY is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AHKSY and does not buy, sell, or trade any shares of AHKSY. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: